Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global RNA interference (RNAi) therapeutics market was valued at USD 5.50 billion in 2025. The market is projected to grow from USD 6.27 billion in 2026 to USD 18.00 billion by 2034, exhibiting a CAGR of 14.1% during the forecast period.
RNA interference (RNAi) therapeutics is emerging as an exponential growth area within precision medicine. RNAi therapies can silence disease-causing genes at the messenger RNA level. Unlike conventional drugs, these therapeutic solutions reduce the production of harmful proteins by targeting specific genetic messages. This makes them highly useful for diseases driven by clearly defined genetic or molecular targets. Furthermore, the market is gaining momentum as RNAi therapies move beyond rare diseases into larger treatment areas such as cardiometabolic diseases, hematology, and chronic liver-related disorders, creating wider opportunities for product development and commercialization.
Furthermore, new product launches, pipeline expansion, and partnerships by key operating companies strengthen their market position and support global market growth.
Rising Adoption of Gene-Silencing Therapies to Treat Genetically Driven Diseases
The global market is growing as these gene-silencing therapies can directly target the genetic source of disease. Many rare and chronic diseases are caused by abnormal protein production, and RNAi therapies reduce this protein production by silencing specific messenger RNA. This targeted action improves treatment precision, supports better clinical outcomes, and encourages physicians, patients, and payers to adopt RNAi-based drugs where conventional therapies have limited disease-modifying impact. This has been observed as more approved RNAi products demonstrate clinical benefit across diseases. Pharmaceutical companies are increasing investment in RNAi platforms and expanding development into larger patient populations.
Download Free sample to learn more about this report.
According to Alnylam Pharmaceuticals, Inc., there are three types of PH: type 1 (PH1), type 2 (PH2), and type 3 (PH3). PH1 is the most common and the most severe form, accounting for 70% to 80% of all cases. PH1 affects approximately four individuals per million in the U.S. and Europe, with an estimated 1,300 to 2,100 diagnosed cases.
High Treatment Cost and Specialty Access Requirements May Limit Wider Product Adoption
The global market faces a major restraint as most approved RNAi therapies are specialty medicines used for rare or complex diseases. These therapies require advanced discovery platforms, complex manufacturing, targeted delivery systems, and specialist-led patient management, which increases overall treatment cost. As a result, even when RNAi therapies show strong clinical value, their adoption can be slowed by reimbursement review, prior authorization, payer restrictions, and uneven access across countries. This creates a gap between clinical innovation and commercial uptake, especially in price-sensitive markets where healthcare systems may delay or restrict access to high-cost specialty drugs.
Growing Development of Extrahepatic RNAi Delivery Platforms to Open Doors to Untapped Treatment Areas
The global RNAi therapeutics market has a strong growth opportunity as companies develop delivery platforms that can move RNAi activity beyond the liver. At present, most approved RNAi products are liver-targeted as hepatocyte delivery is well established through GalNAc and lipid nanoparticle technologies. However, many high-value diseases affect tissues such as muscle, lung, heart, and the central nervous system, where commercial RNAi options are still limited. As extrahepatic delivery improves, companies can expand RNAi therapeutics into neuromuscular, pulmonary, cardiovascular, and other hard-to-treat diseases, which will increase the addressable patient population and create new revenue opportunities beyond the current rare liver-focused base.
|
By Product |
By Molecule Type |
By Therapeutic Area |
By Route of Administration |
By Distribution Channel |
By Region |
|
· ONPATTRO · AMVUTTRA · GIVLAARI · OXLUMO · LEQVIO · RIVFLOZA · QFITLIA · Others |
· siRNA · shRNA · miRNA-based Therapeutics · Others |
· Cardiometabolic Diseases · Rare Genetic Diseases · Hepatic Diseases · Oncology · Others |
· Subcutaneous · Intravenous · Others |
· Hospital Pharmacies · Specialty Pharmacies · Retail/Online Pharmacies · Others |
· North America (U.S. and Canada) · Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific) · Latin America (Brazil, Mexico, and the Rest of Latin America) · Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa) |
The report covers the following key insights:
Based on product, the global RNA interference (RNAi) therapeutics market is segmented into ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, LEQVIO, RIVFLOZA, QFITLIA, and others.
The AMVUTTRA segment is likely to dominate the market. It has expanded from hereditary transthyretin-mediated amyloidosis with polyneuropathy into ATTR amyloidosis with cardiomyopathy, which has a larger diagnosed and treated patient base. This wider indication increases the number of eligible patients, while subcutaneous dosing improves convenience compared with older infusion-based RNAi treatment. As a result, AMVUTTRA has become the strongest revenue-generating RNAi product and is expected to hold the largest product-level share in the market.
Based on molecule type, the market is segmented into siRNA, shRNA, miRNA-based Therapeutics, and others.
The siRNA segment is likely to hold largest share in the market given that nearly all commercially approved RNAi therapeutics are siRNA-based products. Approved RNAi drugs use siRNA to degrade disease-related messenger RNA and reduce harmful protein production. In comparison, shRNA and miRNA-based therapeutics remain mainly in research or clinical-stage development and have limited commercial contribution. As a result, the market is currently shaped by siRNA products, while shRNA and miRNA-based therapeutics are expected to remain emerging categories until more approvals are achieved.
Based on therapeutic area, the market is segmented into cardiometabolic diseases, rare genetic diseases, hepatic diseases, oncology, and others.
The rare genetic diseases segment captured significant share in the RNA interference (RNAi) therapeutics market. The first approved RNAi therapies was developed for rare, genetically defined disorders where the disease-causing protein or pathway is well understood. These diseases often have high unmet need, limited treatment alternatives, and strong specialty-drug pricing. These factors allow RNAi therapies to generate considerable revenue even with smaller patient populations.
Based on route of administration, the market is segmented into subcutaneous, intravenous, and others.
The subcutaneous administration segment dominated the market as most new RNAi therapeutics are designed for convenient injection instead of intravenous infusion. Subcutaneous dosing reduces treatment burden, supports outpatient administration, and improves patient convenience for chronic or long-term diseases. As companies continue to develop GalNAc-conjugated RNAi drugs, the market is shifting away from infusion-based products. This makes subcutaneous administration the strongest segment in the market.
Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail/online pharmacies, and others.
The specialty pharmacies segment is likely to dominate the market as RNAi therapeutics are high-value specialty medicines used for rare or complex diseases. These products often require benefits verification, prior authorization, cold-chain or specialty handling, patient onboarding, adherence support, and coordination with hospitals or specialist clinics. As a result, specialty pharmacies play a central role in ensuring access, reimbursement support, and continuity of therapy. Hospital pharmacies remain important for physician-administered or infusion-based treatment. Nevertheless, specialty pharmacies are expected to account for the largest share due to the growing use of subcutaneous RNAi products in outpatient specialty care.
Request for Customization to gain extensive market insights.
The market, on the basis of region, is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for approximately 45.0% of the global RNA interference (RNAi) therapeutics market in 2025. The regional market is growing given that the region has a strong regulatory pathway for innovative therapies, a large specialty-drug ecosystem, and faster adoption of precision medicines for rare and chronic diseases. The U.S. has been an early approval market for several RNAi products, which gives companies confidence to launch therapies, expand indications, and invest in long-term clinical studies. In addition, the presence of leading RNAi companies, specialist treatment centers, and reimbursement support programs helps patients access high-value RNAi. Increasing research and development activities further support North America market growth.
The Europe market is expected to grow at a significant CAGR during the forecast period. The regulatory approvals are expanding RNAi use from rare disease treatment into broader cardiometabolic and amyloidosis-related indications leading to growth in the region. European healthcare systems are increasingly recognizing targeted gene-silencing therapies where long-term disease control and reduced treatment burden can improve patient outcomes. As more RNAi products receive European authorization, physicians gain more confidence in prescribing these therapies, while companies get stronger commercial visibility across major European markets.
The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The regional RNAi therapeutics market as countries such as Japan and China are gradually adding advanced RNAi products into their treatment landscape for rare diseases and cardiometabolic disorders. The region has a large patient pool for chronic diseases, growing specialist access, and increasing regulatory acceptance of innovative RNA-based therapies. As approved products expand in Japan and China, RNAi therapeutics are expected to move from limited rare-disease use toward broader adoption in cardiovascular and specialty-care settings.
The global RNA interference (RNAi) therapeutics market is moderately fragmented but increasingly consolidating.
The report includes the profiles of the following key players.
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.